Randomized phase III trial comparing the new potent and selective third- generation aromatase inhibitor vorozole with megestrol acetate in postmenopausal advanced breast cancer patients

Journal of Clinical Oncology

Volumn 17, Issue 1, 1999, Pages 52-63

  Goss, Paul E ^a   Winer, E P ^a   Tannock, I F ^a   Schwartz, L H ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; AROMATASE INHIBITOR; LETROZOLE; MEGESTROL ACETATE; VOROZOLE;

ADULT; ADVANCED CANCER; AGED; ANOREXIA; ARTHRALGIA; ARTICLE; BREAST CANCER; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME INHIBITION; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; NAUSEA; PARESTHESIA; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; PRIORITY JOURNAL; UPPER RESPIRATORY TRACT INFECTION; WELLBEING;

EID: 0032941209     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/jco.1999.17.1.52     Document Type: Article

References (45)

1. Miller WR: Aromatase inhibitors in the treatment of advanced breast cancer. Cancer Treat Rev 16:83-93, 1989
2. Hemsell DL, Grodin JM, Brenner PF, et al: Plasma precursors of estrogen: II. Correlation of the extent of conversion of plasma androstenedione to estrone with age. J Clin Endocrinol Metab 38:476-479, 1974
3. Brodie AM, Coombes RC, Dowsett M: Aromatase inhibitors: basic and clinical studies. J Steroid Biochem Mol Biol 27:899-903, 1987
4. Bolufer P, Ricart E, Lluch A, et al: Aromatase activity and estradiol in human breast cancer: Its relationship to estradiol and epidermal growth factor receptors and to tumor-node-metastasis staging. J Clin Oncol 10:438-446, 1992
5. Mouridsen H, Palshof T, Patterson J, et al: Tamoxifen in advanced breast cancer. Cancer Treat Rev 5:131-141, 1978
6. Jordan VC: Tamoxifen for breast cancer prevention. Proc Soc Exp Biol Med 208:144-149, 1995
7. Gockerman JP, Spremulli EN, Raney M, et al: Randomized comparison of tamoxifen versus diethylstilbestrol in estrogen receptor-positive or unknown metastatic breast cancer: A Southeastern Cancer Study Group trial. Cancer Treat Rep 70:1199-1203, 1986
8. Ingle JN, Ahmann DL, Green SJ, et al: Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 5:155-160, 1982
9. Muss HB, Case LD, Capizzi RL, et al: High- versus standard-dose megestrol acetate in women with advanced breast cancer: A phase III trial of the Piedmont Oncology Association. J Clin Oncol 8:1797-1805, 1990
10. Lundgren S, Gundersen S, Klepp R, et al: Megestrol acetate versus aminoglutethimide for metastatic breast cancer. Breast Cancer Res Treat 14:201-206, 1989
11. Paterson AH, Hanson J, Pritchard KI, et al: Comparison of antiestrogen and progestogen therapy for initial treatment and consequences of their combination for second line treatment of recurrent breast cancer. Semin Oncol 17:52-62, 1990
12. Willemse PH, van der Ploeg E, Sleijfer DTH, et al: A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 26:337-343, 1990
13. Espie M: Megestrol acetate in advanced breast carcinoma. Oncology 51:8-12, 1994 (suppl 1)
14. Henderson IC: Endocrine therapy in metastatic breast cancer, in Harris JR, Hellman S, Henderson IC, et al (eds): Breast Diseases (ed 2). Philadelphia, PA, Lippincott, 1991, pp 419-422
15. Cruz JM, Muss HB, Brockschmidt JK, et al: Weight changes in women with metastatic breast cancer treated with megestrol acetate: A comparison of standard versus high-dose therapy. Semin Oncol 17:63-67, 1990 (suppl 9)
16. Goldhirsch A, Gelber RD: Endocrine therapies of breast cancer. Semin Oncol 23:494-505, 1996
17. Ibrahim NK, Buzdar AU: Aromatase inhibitors: Current status. Am J Clin Oncol 18:407-417, 1995
18. Coombes RC, Hughes SW, Dowsett M: 4-Hydroxyandrostenedione: A new treatment for postmenopausal patients with breast cancer. Eur J Cancer 28A:1941-1945, 1992
19. Coombes RC, Stein R, Dowsett M: Aromatase inhibitors in human breast cancer. Proc R Soc Edinb [Biol] 95:283-292, 1989
20. Buzdar AU, Jonat W, Howell A, et al: Anastrozole, a potent and selective aromatase inhibitor versus megestrol acetate in postmenopausal women with advanced breast cancer: Results of overview analysis of two phase III trials. J Clin Oncol 14:2000-2011, 1996
21. Dombemowky P, Smith I, Falkson G, et al: Letrozole, a new oral aromatase inhibitor for advanced breast cancer: Double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate. J Clin Oncol 16:453-461, 1998
22. Wouters W, Van Ginckel R, Krekels M, et al: Pharmacology of vorozole. J Steroid Biochem Mol Biol 44:617-621, 1993
23. Johnston SRD, Smith IE, Doody D, et al: Clinical and endocrine effects of the oral aromatase inhibitor vorozole in postmenopausal patients with advanced breast cancer. Cancer Res 54:5875-5881, 1994
24. Amoroso D, Boccardo F, Balestrero M, et al: Phase II study of vorozole as second line therapy in postmenopausal patients with advanced breast cancer: Preliminary results of a multicentric trial. Ann Oncol 5:33, 1994 (suppl 8)
25. van der Wall E, Donker TH, de Frankrijker E, et al: Inhibition of the in vivo conversion of androstenedione to estrone by the aromatase inhibitor vorozole in healthy postmenopausal women. Cancer Res 53:4563-4566, 1993
26. de Jong PC, van de Ven J, Nortier JWR, et al: Inhibition of breast cancer tissue aromatase activity and estrogen concentrations by the third generation aromatase inhibitor vorozole. Cancer Res 57:2109-2111, 1997
27. Piccart M, Roy JA: Phase II studies with vorozole (Rivizor) in advanced breast cancer. 7th EORTC Breast Cancer Working Conference, Bordeaux, France, September 11-14, 1996 (abstr)
28. Handbook for Reporting Results of Cancer Treatment. WHO publication no. 48. Geneva, Switzerland, World Health Organization, 1979
29. Schipper H, Clinch J, McMurray A, et al: Measuring the quality of life of cancer patients: The Functional Living Index-Cancer: Development and validation. J Clin Oncol 2:472-483, 1984
30. Schoenfeld DA: Sample-size formula for the proportional-hazards regression model. Biometrics 39:499-503, 1983
31. Mantel N: Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer Chemother Rep 50:163-170, 1966
32. Kaplan EL, Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53:457-481, 1958
33. Cox DR: Regression models and life tables (with discussion). J R Stat Soc B 34:187-220, 1972
34. Tonkin K, Tritchler D, Tannock I: Criteria of tumor response used in clinical trials of chemotherapy. J Clin Oncol 3:870-875, 1985
35. Robertson JFR, Williams MR, Todd J, et al: Factors predicting the response of patients with advanced breast cancer to endocrine (Megace) therapy. Eur J Cancer Clin Oncol 25:469-475, 1989
36. Congdon J, Green S, O'Sullivan J, et al: Megestrol acetate (MA) and aminoglutethimide/hydrocortisone (Ag/HC) in sequence or combination as second-line endocrine therapy of estrogen receptor positive metastatic breast cancer. Proc Am Soc Clin Oncol 10:93a, 1991 (abstr 45)
37. Dixon AR, Jackson L, Chan S, et al: A randomised trial of second-line hormone vs single agent chemotherapy in tamoxifen resistant advanced breast cancer. Br J Cancer 66:402-404, 1992
38. Mercer PM, Ebbs SR, Fraser SC, et al: Trial of aminoglutethimide vs hydrocortisone as second-line hormone treatment of advanced breast cancer. Eur J Surg Oncol 19:254-258, 1993
39. Pronzato P, Rubagotti A, Amoroso D, et al: Second-line hormonotherapy for breast cancer: Uselessness of first-line continuation. Am J Clin Oncol 16:522-525, 1993
40. Buzdar A, Jonat W, Howell A, et al: Significant improved survival with Arimidex® (anastrozole) versus megestrol acetate in postmenopausal advanced breast cancer: Updated results of two randomized trials. Proc Am Soc Clin Oncol 16:156a, 1997 (abstr 545)
41. Short R: Survival times prolonged with letrozole in advanced breast cancer. Eur J Cancer 33:5, 1997
42. de Haes JCJM, van Knippenberg FCE, Neijt JP: Measuring psychological and physical distress in cancer patients: Structure and application of the Rotterdam Symptom Checklist. Br J Cancer 66:402-404, 1992
43. Aaronson NK, Ahmedzai S, Bullinger M, et al: The EORTC core quality-of-life questionnaire: Interim results of an international field study, in Osaba D (ed): Effect of Cancer on Quality of Life. London, United Kingdom, CRC, 1991, pp 185-203
44. Weinfurt KP, Wait SL, Boyko W, et al: Psychosocial quality of life in a phase III trial of letrozole. Proc Am Soc Clin Oncol 17:108a, 1998 (abstr 417)
45. Bergh J, Bonneterre J, Illiger HJ, et al: Vorozole (Rivizor™) versus aminoglutethimide in the treatment of postmenopausal breast cancer relapsing after tamoxifen. Proc Am Soc Clin Oncol 16:155a, 1997 (abstr 543)